Risks and Mechanisms of Preeclampsia

封面

如何引用文章

全文:

详细

BACKGROUND: Preeclampsia is a specific pregnancy complication associated with a high cardiovascular risk in both mothers and neonates. Recent research has focused on understanding its underlying mechanisms, which involve differential methylation of cytosine-phosphate-guanine islands and alterations in microRNA expression, genetic and epigenetic factors, and various biomolecules involved in inflammation, oxidative stress, and angiogenesis, etc. Through all these mechanisms, preeclampsia-induced vascular abnormalities may be linked with the pathogenesis of potential cardiovascular diseases. This review explores the diverse mechanisms underlying preeclampsia and the associated cardiovascular changes in pregnant women. The review findings may inform potential strategies for early diagnosis and targeted treatment of preeclampsia.

AIM: to analyze published data on the risks and pathophysiological mechanisms of preeclampsia.

The review was conducted in 2024 using the eLibrary and PubMed databases. The following search queries were used: риски развития преэклампсии (risks of preeclampsia), механизмы развития преэклампсии (mechanisms of preeclampsia), осложнения при преэклампсии (complications of preeclampsia), and сердечно-сосудистые заболевания как осложнение преэклампсии (cardiovascular diseases as a complication of preeclampsia). Currently, there is no consensus regarding the true etiology of preeclampsia. It is often referred to as a disease of theories, which may reflect the fact that the primary biological mechanisms connecting clinical and epidemiological data with organ dysfunction, remain elusive. Despite the lack of definitive evidence, many experts favor the hypothesis that preeclampsia is a primary placental disease. Ongoing efforts are focused on developing effective strategies for screening, diagnosis, treatment, and improving maternal postpartum cardiovascular outcomes.

CONCLUSION: Preeclampsia is a pregnancy-specific complication with a multifactorial etiology, involving abnormal placentation, endothelial dysfunction, systemic inflammation, and oxidative stress. Despite advancements in understanding its underlying mechanisms, effective prevention and treatment options remain limited. The increased risk of cardiovascular diseases in women with preeclampsia may be associated with genetic predisposition, epigenetic modifications during pregnancy, and placental abnormalities.

作者简介

Elena Rudaeva

Kemerovo State Medical University

编辑信件的主要联系方式.
Email: rudaevaeg1951@mail.ru
ORCID iD: 0000-0002-6599-9906
SPIN 代码: 8450-3464

MD, Cand. Sci. (Medicine), Associate Professor

俄罗斯联邦, 22a, Voroshilova str., Kemerovo, 650029

Vadim Mozes

Kemerovo State University

Email: vadimmozes@mail.ru
ORCID iD: 0000-0002-3269-9018
SPIN 代码: 5854-6890

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, 6, Red st., Kemerovo, 650000

Vasily Kashtalap

Research Institute for Complex Issues of Cardiovascular Diseases

Email: v_kash@mail.ru
ORCID iD: 0000-0003-3729-616X
SPIN 代码: 8816-7409

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, 6, Sosnovy Boulevard, Kemerovo, 650002

Svetlana Elgina

Kemerovo State Medical University

Email: elginas.i@mail.ru
ORCID iD: 0000-0002-6966-2681
SPIN 代码: 7696-6446

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, 22a, Voroshilova str., Kemerovo, 650029

参考

  1. Bartsch E, Medcalf KE, Park AL, et al. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016;353: i1753. doi: 10.1136/bmj.i1753
  2. Hecht JL, Ordi J, Carrilho C, et al. The pathology of eclampsia: An autopsy series. Hypertens Pregnancy. 2017;36(3):259–268. doi: 10.1080/10641955.2017.1329430
  3. Leslie MS, Briggs LA. Preeclampsia and the Risk of Future Vascular Disease and Mortality: A Review. J Midwifery Womens Health. 2016;61(3): 315–324. doi: 10.1111/jmwh.12469
  4. Tangren JS, Powe CE, Ankers E, et al. Pregnancy Outcomes after Clinical Recovery from AKI. J Am Soc Nephrol. 2017;28(5):1566–1574. doi: 10.1681/ASN.2016070806
  5. Hecht JL, Zsengeller ZK, Spiel M, et al. Revisiting decidual vasculopathy. Placenta. 2016;42:37–43. doi: 10.1016/j.placenta.2016.04.006
  6. Goel A, Maski MR, Bajracharya S, et al. Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. Circulation. 2015;132(18):1726–1733. doi: 10.1161/CIRCULATIONAHA.115.015721
  7. Gray KJ, Saxena R, Karumanchi SA. Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis. Am J Obstet Gynecol. 2018;218(2):211–218. doi: 10.1016/j.ajog.2017.11.562
  8. McGinnis R, Steinthorsdottir V, Williams NO, et al. Variants in the fetal genome near FLT1 are associated with risk of preeclampsia. Nat Genet. 2017;49(8):1255–1260. doi: 10.1038/ng.3895
  9. Cindrova-Davies T, van Patot MT, Gardner L, et al. Energy status and HIF signalling in chorionic villi show no evidence of hypoxic stress during human early placental development. Mol Hum Reprod. 2015;21(3):296–308. doi: 10.1093/molehr/gau105
  10. Fu J, Zhao L, Wang L, Zhu X. Expression of markers of endoplasmic reticulum stress-induced apoptosis in the placenta of women with early and late onset severe pre-eclampsia. Taiwan J Obstet Gynecol. 2015;54(1):19–23. doi: 10.1016/j.tjog.2014.11.002
  11. Rätsep MT, Felker AM, Kay VR, et al. Uterine natural killer cells: supervisors of vasculature construction in early decidua basalis. Reproduction. 2015;149(2):R91–102. doi: 10.1530/REP-14-0271
  12. Girardi G. Complement activation, a threat to pregnancy. Semin Immunopathol. 2018;40(1):103–111. doi: 10.1007/s00281-017-0645-x
  13. Lynch AM, Murphy JR, Byers T, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol. 2008;198(4):385.e1–9. doi: 10.1016/j.ajog.2007.10.793
  14. Sones JL, Merriam AA, Seffens A, et al. Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia. FASEB J. 2018;32(5):2574–2586. doi: 10.1096/fj.201701008R
  15. Vaught AJ, Braunstein EM, Jasem J, et al. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight. 2018;3(6): e99128. doi: 10.1172/jci.insight.99128
  16. Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13(2):300–317. doi: 10.2215/CJN.00620117
  17. Szalai G, Romero R, Chaiworapongsa T, et al. Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice. PLoS One. 2015;10(4):e0119547. doi: 10.1371/journal.pone.0119547
  18. March MI, Geahchan C, Wenger J, et al. Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia. PLoS One. 2015;10(5):e0126815. doi: 10.1371/journal.pone.0126815
  19. Saleh L, Verdonk K, Visser W, et al. The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia. Ther Adv Cardiovasc Dis. 2016;10(5):282–293. doi: 10.1177/1753944715624853
  20. Quitterer U, Fu X, Pohl A, et al. Beta-Arrestin1 Prevents Preeclampsia by Downregulation of Mechanosensitive AT1-B2 Receptor Heteromers. Cell. 2019;176(1–2):318–333.e19. doi: 10.1016/j.cell.2018.10.050
  21. Zhang HH, Chen JC, Sheibani L, et al. Pregnancy Augments VEGF-Stimulated In Vitro Angiogenesis and Vasodilator (NO and H2S) Production in Human Uterine Artery Endothelial Cells. J Clin Endocrinol Metab. 2017;102(7):2382–2393. doi: 10.1210/jc.2017-00437
  22. Zeng Y, Li M, Chen Y, Wang S. Homocysteine, endothelin-1 and nitric oxide in patients with hypertensive disorders complicating pregnancy. Int J Clin Exp Pathol. 2015;8(11):15275–15279. PMID: 26823880
  23. Osol G, Ko NL, Mandalà M. Altered Endothelial Nitric Oxide Signaling as a Paradigm for Maternal Vascular Maladaptation in Preeclampsia. Curr Hypertens Rep. 2017;19(10):82. doi: 10.1007/s11906-017-0774-6
  24. Chisholm KM, Folkins AK. Placental and Clinical Characteristics of Term Small-for-Gestational-Age Neonates: A Case-Control Study. Pediatr Dev Pathol. 2016;19(1):37–46. doi: 10.2350/15-04-1621-OA.1
  25. Baltajian K, Bajracharya S, Salahuddin S, et al. Sequential plasma angiogenic factors levels in women with suspected preeclampsia. Am J Obstet Gynecol. 2016;215(1):89.e1–89.e10. doi: 10.1016/j.ajog.2016.01.168
  26. Rana S, Salahuddin S, Mueller A, et al. Angiogenic biomarkers in triage and risk for preeclampsia with severe features. Pregnancy Hypertens. 2018;13:100–106. doi: 10.1016/j.preghy.2018.05.008
  27. Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1: PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374(1):13–22. doi: 10.1056/NEJMoa1414838
  28. Zeisler H, Llurba E, Chantraine FJ, et al. The sFlt-1/PlGF Ratio: ruling out preeclampsia for up to 4 weeks and the value of retesting. Ultrasound in Obstetrics and Gynecology. 2019;53(3):367–375. doi: 10.1002/uog.19178
  29. Leaños-Miranda A, Campos-Galicia I, Berumen-Lechuga MG, et al. Circulating Angiogenic Factors and the Risk of Preeclampsia in Systemic Lupus Erythematosus Pregnancies. J Rheumatol. 2015;42(7):1141–1149. doi: 10.3899/jrheum.141571
  30. Kim MY, Buyon JP, Guerra MM, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016;214(1):108.e1–108.e14. doi: 10.1016/j.ajog.2015.09.066
  31. Chaiworapongsa T, Romero R, Whitten AE, et al. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med. 2016;29(8):1214–1228. doi: 10.3109/14767058.2015.1048431
  32. Sovio U, Gaccioli F, Cook E, et al. Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women. Hypertension. 2017;69(4):731–738. doi: 10.1161/HYPERTENSIONAHA.116.08620
  33. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017;377(7): 613–622. doi: 10.1056/NEJMoa1704559
  34. Charkiewicz K, Jasinska E, Laudanski P. Mikromacierze białkowe i tandemowa spektrometria mas w poszukiwaniu proteomicznych biomarkerów preeklampsji [Identification of proteomic biomarkers of preeclampsia using protein microarray and tandem mass spectrometry]. Postepy Hig Med Dosw (Online). 2015;69:562–570. [In Polish] doi: 10.5604/17322693.1151286
  35. Law KP, Han TL, Tong C, Baker PN. Mass spectrometry-based proteomics for pre-eclampsia and preterm birth. Int J Mol Sci. 2015;16(5): 10952–10985. doi: 10.3390/ijms160510952
  36. Makris A, Yeung KR, Lim SM, et al. Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates. Hypertension. 2016;67(6):1263–1272. doi: 10.1161/HYPERTENSIONAHA.116.07286
  37. Spradley FT, Tan AY, Joo WS, et al. Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension. Hypertension. 2016;67(4):740–747. doi: 10.1161/HYPERTENSIONAHA.115.06783
  38. Santiago-Font JA, Amaral LM, Faulkner J, et al. Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia. Am J Physiol Regul Integr Comp Physiol. 2016;311(6):R1158–R1163. doi: 10.1152/ajpregu.00192.2016
  39. Ashar-Patel A, Kaymaz Y, Rajakumar A, et al. FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia. Sci Rep. 2017;7(1):12139. doi: 10.1038/s41598-017-11639-6
  40. Turanov AA, Lo A, Hassler MR, et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat Biotechnol. 2018:10.1038/nbt.4297. doi: 10.1038/nbt.4297
  41. Paauw ND, Terstappen F, Ganzevoort W, et al. Sildenafil During Pregnancy: A Preclinical Meta-Analysis on Fetal Growth and Maternal Blood Pressure. Hypertension. 2017;70(5):998–1006. doi: 10.1161/HYPERTENSIONAHA.117.09690
  42. Trapani A Jr, Gonçalves LF, Trapani TF, et al. Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment: A Randomized Controlled Trial. Obstet Gynecol. 2016;128(2):253–259. doi: 10.1097/AOG.0000000000001518
  43. Pels A, Kenny LC, Alfirevic Z, et al. STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials. BMC Pregnancy Childbirth. 2017;17(1):440. doi: 10.1186/s12884-017-1594-z
  44. Kalafat E, Sukur YE, Abdi A, et al. Thilaganathan B, Khalil A. Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. Ultrasound Obstet Gynecol. 2018;52(6):706–714. doi: 10.1002/uog.19084
  45. Brownfoot FC, Hastie R, Hannan NJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 2016;214(3):356.e1–356.e15. doi: 10.1016/j.ajog.2015.12.019
  46. Cluver CA, Hannan N, van Papendorp E, et al. Esomeprazole to treat women with preterm preeclampsia: a randomised placebo controlled trial. Am J Obstet Gynecol. 2018:219(4):388.e1–388.e17. doi: 10.1016/j.ajog.2018.07.019 46
  47. Kaitu’u-Lino TJ, Brownfoot FC, Beard S, et al. Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction — implications for treating preeclampsia. PLoS One. 2018;13(2): e0188845. doi: 10.1371/journal.pone.0188845
  48. Thadhani R, Hagmann H, Schaarschmidt W, et al. Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. J Am Soc Nephrol. 2016;27(3):903–913. doi: 10.1681/ASN.2015020157
  49. Haddad B, Winer N, Chitrit Y, et al. Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial. Obstet Gynecol. 2016;128(5):1053–1063. doi: 10.1097/AOG.0000000000001673
  50. Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2018;218(3):287–293.e1. doi: 10.1016/j.ajog.2017.11.561
  51. Covarrubias AE, Lecarpentier E, Lo A, et al. AP39, a Modulator of Mitochondrial Bioenergetics, Reduces Antiangiogenic Response and Oxidative Stress in Hypoxia-Exposed Trophoblasts: Relevance for Preeclampsia Pathogenesis. Am J Pathol. 2019;189(1):104–114. doi: 10.1016/j.ajpath.2018.09.007
  52. Vaka VR, McMaster KM, Cunningham MW Jr, et al. Role of Mitochondrial Dysfunction and Reactive Oxygen Species in Mediating Hypertension in the Reduced Uterine Perfusion Pressure Rat Model of Preeclampsia. Hypertension. 2018;72(3):703–711. doi: 10.1161/HYPERTENSIONAHA.118.11290
  53. Shahul S, Medvedofsky D, Wenger JB, et al. Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy. Hypertension. 2016;67(6):1273–1280. doi: 10.1161/HYPERTENSIONAHA.116.07252
  54. Tangren JS, Powe CE, Ankers E, et al. Pregnancy Outcomes after Clinical Recovery from AKI. J Am Soc Nephrol. 2017;28(5):1566–1574. doi: 10.1681/ASN.2016070806.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-Vector, 2025

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».